Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$1,049 Mln
Revenue (TTM)
$511 Mln
Net Profit (TTM)
$0 Mln
ROE
0.4 %
ROCE
-- %
P/E Ratio
7
P/B Ratio
1
Industry P/E
--
EV/EBITDA
2.8
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$0.9
Face value
--
Shares outstanding
225,172,749
CFO
€-920.37 Mln
EBITDA
€-1,127.52 Mln
Net Profit
€-1,215.77 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
CureVac NV (CVAC)
| 3.1 | -9.0 | -14.5 | 28.7 | -9.9 | -44.2 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
|---|---|---|---|---|
|
CureVac NV (CVAC)
| 32.6 | -30.2 | -82.4 | -57.7 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
CureVac NV (CVAC)
|
4.7 | 1,049.3 | 510.5 | 193.6 | -21.7 | 25.5 | 7 | 1.0 |
| 0.1 | 3.0 | 0.9 | -70.0 | -7,823.0 | -241.9 | -- | 0.1 | |
| 0.1 | 9.4 | 48.5 | -35.5 | -117.5 | 397.6 | -- | 0.9 | |
| 0.9 | 60.1 | 0.0 | -43.8 | -173,594.0 | -85.1 | -- | 1.4 | |
| 1.7 | 45.8 | 5.0 | -23.3 | -442.3 | -121 | -- | 3.6 | |
| 28.6 | 1,772.7 | 0.0 | -163.7 | -- | -60.9 | -- | 4.7 | |
| 1.7 | 159.1 | 15.3 | -40.5 | -271.2 | -58.8 | -- | 2.9 |
As of December 18, 2025, CureVac N.V. was acquired by BioNTech SE. CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company's portfolio includes clinical... and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs human cells to produce or secrete specific proteins in the nucleus, cytoplasm, cellular organelles, and cell membrane. In addition, the company offers The RNA Printer, a downsized, integrated, and highly automated process for manufacturing of mRNA vaccines and therapeutics. Further, it develops prophylactic vaccine lead candidate that addresses urinary tract infections targeting uropathogenic E. coli (UPEC) bacteria; vaccine candidates CV0601 and CV0701, which are in phase 2 clinical study against SARS-CoV-2; vaccines for off-the-shelf and fully personalized cancer precision immunotherapies in oncology; and CVGBM for treating cancer. Additionally, the company develops, manufactures, and commercializes mRNA vaccines targeting SARS-CoV-2 variants; antigen cancer precision immunotherapy candidate that targets squamous non-small cell lung cancer; and antigen cancer precision immunotherapy candidate CVGBM that is tested in patients with surgically resected MGMT-unmethylated glioblastoma or astrocytoma with a molecular signature of glioblastoma. CureVac N.V. was incorporated in 2000 and is headquartered in Tübingen, Germany. Read more
MD, CFO & Member of Management Board
Mr. Pierre Kemula B.Sc.
MD, CFO & Member of Management Board
Mr. Pierre Kemula B.Sc.
Headquarters
Tübingen
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of CureVac NV (CVAC) is $4.66 (NASDAQ) as of 06-Jan-2026 09:30 EDT. CureVac NV (CVAC) has given a return of -9.94% in the last 3 years.
The P/E ratio of CureVac NV (CVAC) is 6.96 times as on 06-Jan-2026.
The P/B ratio of CureVac NV (CVAC) is 1.03 times as on 06-Jan-2026, a 80 discount to its peers’ median range of 5.06 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
4.72
|
1.10
|
|
2023
|
-3.62
|
1.82
|
|
2022
|
-4.58
|
2.14
|
|
2021
|
-15.04
|
8.99
|
|
2020
|
-113.35
|
20.57
|
The 52-week high and low of CureVac NV (CVAC) are Rs 5.72 and Rs 2.48 as of 03-Apr-2026.
CureVac NV (CVAC) has a market capitalisation of $ 1,049 Mln as on 06-Jan-2026. As per SEBI classification, it is a Small Cap company.
Before investing in CureVac NV (CVAC), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.